December 1, 2020 (Seoul) – Amgen Korea announced on 1st of December that it signed a memorandum of understanding with the Seoul Science Center to cooperate in the ‘Grow Up, Bio Up’ campaign, designed to give children and youth in Korea greater access to life science education and more opportunities to develop their career in science. The signing ceremony was held on November 30, 2020, via virtual conference.
The Grow Up, Bio Up campaign is based on cooperation between the two organization, which have been renowned for their respective expertise in fundamental science, to make basic research, such as biology and genetics, more accessible to the public and provide more opportunities for children and youth to find their career path in science, so that they can become future scientists with strong capabilities in life science. The MoU becomes effective between 2020 and 2022, and Amgen Korea will provide physical support and human resources necessary to operate the program, while the center takes responsibilities for the entire range of operation ranging from planning the curriculum to developing the platforms through running the programs.
Under the MoU, between 2020 and 2021, there will be a project to develop a non-contact hands-on experiment online platform, which will serve as a venue for virtual experiment programs. This platform, which will embody Amgen’s commitment to R&D, described as ‘Biology First’, and the center’s motto of ‘A center of Basic Science for Youth’, will enable children and youth to virtually experience biology experiments. In addition, in 2022, there will be a ‘Grow Up, Bio Up’ camp for children and youth, where they can physically experience various biology experiments as well as science exhibition tours.
“We are thrilled to work with the Seoul Science Center to present a new campaign, ‘Grow Up, Bio Up’ campaign, where children and youth can experience the potential of life science. We hope this cooperation could bring more science geniuses to the next generation of our future science leaders,” said Sang Noh, General Manager, Amgen Korea. “Amgen Korea continues to put priority on life science in our commitment to R&D, which empowers us to bring more innovative biomedicines to patients in Korea. We will keep our constant effort to expand the base of science education and culture that dates back to the Creative Science Camp, which we launched in 2018 to give children opportunities to have fun with science, as a way to fulfil our responsibilities as a corporate citizen.”
“I believe that cooperation with a company renowned for its expertise in life science will help us to develop a new science education program that will give more fun and greater understanding of fundamental science to students,” said Lee Jeong-gyu, Director, Seoul Science Center. “Based on our expertise in science education, we will expand channels for education both online and offline and work with more companies to arouse interest in biology among students.”
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
# # #
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (email@example.com)
Jina Lee (firstname.lastname@example.org)
# # #